FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated average burden				
hours per response				

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			3. Issuer Name and Ticker or Trading Symbol						
	`	ay/10a	ai) Derm	Dermata Therapeutics, Inc. [DRMA]					
01/12/2				1 1 5			5. If Amendment, Date Original		
			Issuer	(Cl. 1			Filed(Month/Day/Year)		
			X D						
			o	Officer (give title Other (specify					
	below)			below)		6. Individual or Joint/Group Filing(Check			
						X Form fi	_X_ Form filed by One Reporting Person		
						Form fil	ed by More than One Reporting Person		
Table I - Non-Derivative Securities Beneficially Owned									
2. Amount of Sec			nt of Securities	curities 3. Ownership 4. Natur			re of Indirect Beneficial Ownership		
		ally Owned							
	(In	istr. 4)		\					
				\ /	r. 5)				
		•	•	•			SEC 1473 (7-02)		
Persons who respond to the collection of information contained in this form are not required to respond									
nays a cui	Tentily van		D control nar	iibei.					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
					4. Conversion	5. Ownership	6. Nature of Indirect Beneficial		
			, ,	g Derivativ		Form of	Ownership		
(Instr. 4)		•				(Instr. 5)			
					(D) or Indirect				
		Title		mber of		(I)			
Shares			Snares			(Instr. 5)			
	of securities de to the colays a cui rities Ber 2. Date Exerand Expirati Month/Day/Ye	Statement (Month/D 01/12/2022 2. Be (In of securities beneficially do to the collection olays a currently valid rities Beneficially 2. Date Exercisable and Expiration Date Month/Day/Year)	Statement (Month/Day/Yes 01/12/2022 2. Amour Beneficial (Instr. 4) of securities beneficially owned to the collection of infolars a currently valid OM rities Beneficially Own 2. Date Exercisable and Expiration Date Month/Day/Year) Oate Expiration Tate Date Expiration Tate Expiration Tate Oate	Statement (Month/Day/Year) 01/12/2022 Table I - Non 2. Amount of Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) of securities beneficially Owned (e.g., putsual Expiration Date Month/Day/Year) 3. Title and Amount Securities Underlying Security (Instr. 4) Date Expiration Table Amount or Number 1 (Instr. 4)	Statement (Month/Day/Year) 01/12/2022 4. Relationship of Issuer (Check aXDirectorOfficer (give title below) Table I - Non-Derivati 2. Amount of Securities Beneficially Owned (Instr. 4) of securities beneficially owned directly or indirectly. Indicate the collection of information contained in the plays a currently valid OMB control number. Titles Beneficially Owned (e.g., puts, calls, word). 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Date Expiration Date Expiration Title Amount or Number of	Statement (Month/Day/Year) 01/12/2022 A. Relationship of Reporting Persont Issuer Check all applicable	Dermata Therapeutics, Inc. [DRMA]		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Bradrick Brittany C/O DERMATA THERAPEUTICS, INC.	X					
3525 DEL MAR HEIGHTS RD., #322 SAN DIEGO, CA 92130						

Signatures

/s/ Gerald T. Proehl, Attorney-in Fact	01/14/2022
**Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Exhibit 24. Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number of the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number of the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number of the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number of the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number of the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number of the collection of the coll	ber.

POWER OF ATTORNEY

Know all by these present that the undersigned hereby constitutes and appoints each of Gerald T. Proehl, Daniel Porco and Steven Skolnick as their true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned Schedules 13D and 13G and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder;
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Schedules 13D or 13G, Form ID application for EDGAR codes, and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and Exchange Commission and any other authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including, without limitation, the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedules 13D and 13G and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Exchange Act and the rules thereunder with respect to the undersigned's holdings of and transactions in securities issued by Dermata Therapeutics, Inc. unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 12, 2021.

/s/ Brittany Bradrick